MK-8690

Phase 2Small molecule

Merck & Co.

MK-8690 is one of 7 small molecule programs targeting Colitis, Ulcerative. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colitis, UlcerativeRecruiting

Colitis, UlcerativePhase 2

Recruiting

Competition

Competitive Landscape

8 competitors in Colitis, Ulcerative

#DrugCompanyPhaseTrials

Tremfya

Johnson & Johnson

Phase 3

4 2

Omvoh

Eli Lilly

Phase 2

1 3

Velsipity

Pfizer

Phase 2

3 4

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

1 5

Zeposia

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 6

MK-8690

Merck & Co.

Phase 2

1 7

Aletekitug

GSK

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Colitis, Ulcerative

NCT07463183

Clinical

Trials by Indication[1]

Colitis, Ulcerative1 trial

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT07463183·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MK-8690. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MK-8690 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MK-8690. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

MK-8690

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Colitis, Ulcerative1 trial

References

Drug Info

Quick Facts

Related News